PA
RPRX icon

Pineridge Advisors’s Royalty Pharma RPRX Stock Holding History

Pineridge Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$3.1K Sell
88
-165
-65% -$5.97K ﹤0.01% 333
2025
Q2 		$9.13K Buy
253
+1
+0.4% +$33 ﹤0.01% 231
2025
Q1 		$7.84K Buy
252
+2
+0.8% +$63 ﹤0.01% 261
2024
Q4 		$6.38K Buy
250
+78
+45% +$2.07K ﹤0.01% 357
2024
Q3 		$4.86K Buy
172
+2
+1% +$55 ﹤0.01% 348
2024
Q2 		$4.49K Buy
+170
New +$4.71K ﹤0.01% 380

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pineridge Advisors's RPRX Position: Q3 2025 in Review

Pineridge Advisors reduced its Royalty Pharma (RPRX) stake by 65% in Q3 2025, selling an estimated $5.97K and leaving 88 shares worth $3.1K. The position accounts for ﹤0.01% of the portfolio, ranked #333.

Pineridge Advisors first reported a position in RPRX in Q2 2024 and has held it in 6 quarters since. The position peaked at $9.13K in Q2 2025. 487 funds tracked by Wall St. Rank hold RPRX as of Q3 2025.

  • Pineridge Advisors held 88 shares of Royalty Pharma worth $3.1K as of Q3 2025.
  • Pineridge Advisors sold 165 Royalty Pharma shares in Q3 2025, an estimated $5.97K.
  • Royalty Pharma made up ﹤0.01% of Pineridge Advisors's portfolio in Q3 2025, its #333 holding.
  • Pineridge Advisors first reported a position in Royalty Pharma in Q2 2024 and has held it in 6 quarters since.
  • Pineridge Advisors's Royalty Pharma position peaked at $9.13K in Q2 2025.
  • 487 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2025.

Based on Pineridge Advisors's 13F filing for Q3 2025, filed 4 Nov 2025.